Takeda Oncology Hopes Hit By CHMP Ninlaro Rejection; Appeal Planned
This article was originally published in The Pink Sheet Daily
Executive Summary
An EMA advisory committee sets back Takeda’s oncology plans by rejecting Ninlaro as a treatment for multiple myeloma in Europe, saying supporting data was inadequate for its backing but the Japanese company aims to appeal the decision.